# Spyre Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Spyre Therapeutics, Inc.). ## Overview Spyre Therapeutics is a U.S.-based clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases. Its pipeline centers on engineered antibodies and antibody combinations targeting α4β7, TL1A, and IL-23, with development activities organized through licensed programs and clinical trials. ## Products & services • SPY001 anti-α4β7 antibody program • SPY002 anti-TL1A antibody program • SPY003 anti-IL-23 antibody program • SPY120 fixed-dose antibody combination program • SPY072 rheumatic disease antibody program - **IBD monotherapy antibodies** (45%) — Single-agent antibody programs for inflammatory bowel disease, including SPY001, SPY002 and SPY003. - **IBD combination therapies** (20%) — Fixed-dose or paired antibody combinations designed to improve efficacy, safety and convenience in IBD. - **Rheumatic disease programs** (20%) — Antibody development for rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. - **Licensing and development rights** (15%) — Exclusive worldwide rights to develop, manufacture and commercialize selected antibody programs. - SPY001 anti-α4β7 antibody program - SPY002 anti-TL1A antibody program - SPY003 anti-IL-23 antibody program - SPY120 fixed-dose antibody combination program - SPY072 rheumatic disease antibody program ## Customers Spyre does not sell commercial products today; its direct counterparties are licensors, research partners, clinical trial participants, and future pharmaceutical buyers such as hospitals, specialists, and payers. The eventual end customers for approved therapies would be patients with IBD or rheumatic diseases, while commercialization would likely run through specialty prescribing channels and reimbursement systems. - **Licensing counterparties** (primary) — Paragon and other IP holders that grant Spyre rights to antibody programs and related know-how. - **Clinical trial participants** (primary) — Healthy volunteers and patients enrolled to generate safety, PK, ADA and efficacy data. - **IBD specialists** (primary) — Gastroenterologists and IBD centers that would prescribe approved therapies for ulcerative colitis and Crohn's disease. - **Rheumatology specialists** (secondary) — Rheumatologists treating RA, PsA and axSpA if the SPY072 program advances successfully. - **Payers and health systems** (secondary) — Commercial and government payers that would determine access and reimbursement for biologic therapies. - Licensors and IP owners that grant development and commercialization rights - Clinical trial participants enrolled in Phase 1 and Phase 2 studies - Future gastroenterologists treating ulcerative colitis and Crohn's disease - Future rheumatologists treating RA, PsA and axSpA - Payers and health systems that would reimburse approved biologics ## Geography Spyre is headquartered in Waltham, Massachusetts and operates as a U.S.-based development company. Its clinical programs are being studied in the United States and, for some trials, in certain other countries including parts of Europe and China through ethnobridging or multi-country enrollment. - Headquartered in Waltham, Massachusetts, United States - Clinical development centered in the United States - Phase 2 IBD studies include the U.S. and certain other countries - SPY072 basket trial initiated in the U.S. and Europe - Chinese ethnobridging cohort used for SPY003 PK comparison ## Strategy Spyre's strategy is to build a portfolio of long-acting antibodies with differentiated pharmacokinetics and to test them both as monotherapies and in combinations. It is also extending the anti-TL1A program into additional immune-mediated diseases, aiming to create a broader platform beyond IBD. - **Advance SPY001, SPY002 and SPY003 through clinical proof-of-concept** (short-term) — These are the core assets that could validate the company's IBD platform and future commercial value. - **Build combination regimens for IBD** (medium-term) — Combining complementary mechanisms may improve efficacy and convenience versus single antibodies. - **Expand SPY072 beyond IBD into rheumatic disease** (medium-term) — A broader indication set can increase the addressable market for the anti-TL1A program. - Advance next-generation monotherapies with improved potency and PK - Develop fixed-dose antibody combinations for IBD - Expand anti-TL1A into RA, PsA and axSpA - Use platform trials to test multiple arms efficiently - Secure external rights to key antibody programs ## Risks Spyre is exposed to the binary risks of clinical-stage drug development, including trial failure, regulatory disagreement, and delays in patient enrollment or study design. It also depends on third-party licensors and manufacturers, and it will need substantial additional capital before any product can be commercialized. - **Clinical development failure** [critical] — The pipeline is still in Phase 1 and Phase 2, so efficacy and safety remain unproven. - **Regulatory and trial-design risk** [high] — FDA or foreign regulators may disagree with platform-trial or basket-trial designs. - **Capital requirements and dilution** [high] — The company funds R&D with external capital and has no commercial revenue base. - **Third-party reliance** [high] — Licensors, CROs and manufacturers control key inputs to development and supply. - **Intellectual property disputes** [medium] — Engineered antibody programs operate in a crowded and litigious patent landscape. - No product sales yet; success depends on future approvals - Clinical trials may fail to show safety, PK or efficacy - Regulatory agencies may not accept trial design or endpoints - Third-party licensors and manufacturers are critical dependencies - Additional financing will likely be needed before commercialization ## Accounting As a clinical-stage biotech, Spyre's reported results are driven mainly by R&D expense accruals, stock-based compensation, and fair-value measurements rather than product revenue. Investors should watch how the company estimates accrued trial costs, values contingent liabilities and equity awards, and accounts for any license or development revenue tied to collaboration arrangements. - **Accrued research and development costs** — Can shift quarterly operating loss and liabilities - **Contingent value right liability** — Fair-value remeasurement can create non-cash volatility - **Stock-based compensation** — Affects operating expense and dilution analysis - **License and development revenue** — Revenue timing may be uneven and contract-specific - R&D accruals depend on estimated CRO and trial vendor costs - Stock-based compensation uses Black-Scholes assumptions - CVR liability is marked using probability and cash-flow estimates - License and development revenue depends on contract terms - Acquired IPR&D and other intangibles may require fair-value judgments --- *Last updated: 2026-04-29T04:59:59.627019+00:00*